Anaplastic ganglioglioma
MONDO:0016734A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO)
Also known as: AGNG
1436 clinical trials for this condition and its sub-types, 2 tagged with Anaplastic ganglioglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Kids' brain tumor drugs tested for Long-Term safety
Disease control OngoingThis study follows 165 children who previously took dabrafenib and/or trametinib for certain brain tumors. Researchers want to see if these drugs are safe over the long term and how they affect growth. The children continue their treatment and are monitored for side effects and d…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo shows promise for kids with aggressive brain tumors
Disease control OngoingThis phase 2 trial tests whether two targeted drugs, dabrafenib and trametinib, can improve outcomes for children and young adults with a specific type of high-grade glioma (BRAF V600-mutant) after they receive radiation therapy. The study enrolls 58 participants aged 25 or young…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC